Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

110.99USD
8 Dec 2016
Change (% chg)

$-0.11 (-0.10%)
Prev Close
$111.10
Open
$110.54
Day's High
$111.19
Day's Low
$109.93
Volume
2,368,721
Avg. Vol
2,275,858
52-wk High
$126.07
52-wk Low
$94.30

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $302,251.09
Shares Outstanding(Mil.): 2,720.53
Dividend: 0.80
Yield (%): 2.88

Financials

  JNJ.N Industry Sector
P/E (TTM): 19.47 30.04 30.65
EPS (TTM): 5.71 -- --
ROI: 14.16 15.86 15.23
ROE: 22.09 16.96 16.56

J&J questions fairness of hip implant trial, $1 billion verdict

Johnson & Johnson will challenge the fairness of a trial that produced a verdict of $1 billion in damages against the company last week over allegations of design flaws in its Pinnacle hip implant.

07 Dec 2016

Analysis: J&J questions fairness of hip implant trial, $1 bln verdict

Johnson & Johnson will challenge the fairness of a trial that produced a verdict of $1 billion in damages against the company last week over allegations of design flaws in its Pinnacle hip implant.

07 Dec 2016

Top Actelion shareholder says backs J&J deal above 246 Sfr/share

LONDON A top-30 investor in Swiss pharmaceutical company Actelion said he would back a takeover approach for the whole company from U.S. rival Johnson & Johnson above 246 Swiss francs.

06 Dec 2016

Trump's corporate tax holiday could spur pharma M&A

U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.

06 Dec 2016

Sanofi exploring bid for Actelion amid J&J talks: Bloomberg

French drugmaker Sanofi is considering a bid for Swiss biotech company Actelion , rivaling an offer made by U.S. healthcare company Johnson & Johnson , Bloomberg reported.

06 Dec 2016

Dealtalk: Trump's corporate tax holiday could spur pharma M&A

U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.

06 Dec 2016

Actelion's silence has hedge funds betting big on J&J deal

ZURICH Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm, betting that Johnson & Johnson's (J&J) approach will result in an outright takeover and handsome returns.

02 Dec 2016

Johnson & Johnson hit with over $1 billion verdict on hip implants

A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

02 Dec 2016

Johnson & Johnson hit with over $1 billion verdict on hip implants

A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

02 Dec 2016

Actelion shares fall on report it rejects J&J offer

ZURICH Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.

30 Nov 2016

Earnings vs. Estimates